Valent et al report criteria for describing the response to theraph shown by a patient with cutaneous mastocytosis. The authors are from multiple universities in North America and Europe.
Parameters:
(1) skin lesions
(2) cutaneous symptoms
(3) frequency of severe symptoms (Grade 4)
|
Percent of Skin Lesions Present |
Duration of Change |
Term |
|
none (all gone) |
|
complete regression |
|
none (all gone) |
>= 2 years |
continuous complete regression |
|
< 50% |
|
major regression |
|
50 to 90% |
|
partial regression |
|
> 90% |
|
no regression |
|
Percent of Cutaneous Symptoms Present |
Duration of Change |
Term |
|
none (all gone) |
|
complete regression |
|
none (all gone) |
>= 2 years |
continuous complete regression |
|
< 50% |
|
major regression |
|
50 to 90% |
|
partial regression |
|
> 90% |
|
no regression |
A major regression in symptoms is also used when there is a significant decrease in the frequency of severe (Grade 4) symptoms:
(1) from more than once a month to less often (from C to B in the frequency level)
(2) from several times a year to less than once a year (from B to A in the frequency level)
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,
